Immunogenicity and reactogenicity of a third dose of BNT162b2 vaccine for COVID-19 after a primary regimen with BBIBP-CorV or BNT162b2 vaccines in Lima, Peru

The administration of a third (booster) dose of COVID-19 vaccines in Peru initially employed the BNT162b2 (Pfizer) mRNA vaccine. The national vaccination program started with healthcare workers (HCW) who received BBIBP-CorV (Sinopharm) vaccine as primary regimen and elderly people previously immuniz...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2022-10, Vol.17 (10), p.e0268419
Main Authors: Vargas-Herrera, Natalia, Fernández-Navarro, Manuel, Cabezudo, Nestor E, Soto-Becerra, Percy, Solís-Sánchez, Gilmer, Escobar-Agreda, Stefan, Silva-Valencia, Javier, Pampa-Espinoza, Luis, Bado-Pérez, Ricardo, Solari, Lely, Araujo-Castillo, Roger V
Format: Article
Language:English
Subjects:
Adverse and side effects
Aged
Aged patients
Antibodies, Viral
Antibody response
Biology and Life Sciences
BNT162 Vaccine
Care and treatment
Comorbidity
Coronaviruses
COVID-19
COVID-19 - prevention & control
COVID-19 vaccines
COVID-19 Vaccines - adverse effects
Drug dosages
Drugs
Evaluation
Homology
Humans
IgG antibody
Immunization
Immunization, Secondary
Immunoassay
Immunogenicity
Immunogenicity, Vaccine
Immunoglobulin G
Infections
Medical personnel
Medicine and Health Sciences
mRNA
mRNA Vaccines
Older people
Peru
Population
Prospective Studies
Severe acute respiratory syndrome
Severe acute respiratory syndrome coronavirus 2
Vaccines
Vaccines, Synthetic
Values
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c692t-bd27ee26b0e7068a37139fd8417686b3269a29248cbe0ace806222e52658e0a23
cites cdi_FETCH-LOGICAL-c692t-bd27ee26b0e7068a37139fd8417686b3269a29248cbe0ace806222e52658e0a23
container_end_page
container_issue 10
container_start_page e0268419
container_title PloS one
container_volume 17
creator Vargas-Herrera, Natalia
Fernández-Navarro, Manuel
Cabezudo, Nestor E
Soto-Becerra, Percy
Solís-Sánchez, Gilmer
Escobar-Agreda, Stefan
Silva-Valencia, Javier
Pampa-Espinoza, Luis
Bado-Pérez, Ricardo
Solari, Lely
Araujo-Castillo, Roger V
description The administration of a third (booster) dose of COVID-19 vaccines in Peru initially employed the BNT162b2 (Pfizer) mRNA vaccine. The national vaccination program started with healthcare workers (HCW) who received BBIBP-CorV (Sinopharm) vaccine as primary regimen and elderly people previously immunized with BNT162b2. This study evaluated the reactogenicity and immunogenicity of the "booster" dose in these two groups in Lima, Peru. We conducted a prospective cohort study, recruiting participants from November to December of 2021 in Lima, Peru. We evaluated immunogenicity and reactogenicity in HCW and elderly patients previously vaccinated with either two doses of BBIBP-CorV (heterologous regimen) or BTN162b2 (homologous regimen). Immunogenicity was measured by anti-SARS-CoV-2 IgG antibody levels immediately before boosting dose and 14 days later. IgG geometric means (GM) and medians were obtained, and modeled using ANCOVA and quantile regressions. The GM of IgG levels increased significantly after boosting: from 28.5±5.0 AU/mL up to 486.6±1.2 AU/mL (p
doi_str_mv 10.1371/journal.pone.0268419
format article
fullrecord <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2725591544</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A722869587</galeid><doaj_id>oai_doaj_org_article_a13afadafa994ded969841584d0b5356</doaj_id><sourcerecordid>A722869587</sourcerecordid><originalsourceid>FETCH-LOGICAL-c692t-bd27ee26b0e7068a37139fd8417686b3269a29248cbe0ace806222e52658e0a23</originalsourceid><addsrcrecordid>eNqNk--K1DAUxYso7rr6BqIBQRDsmCZN2nxZ2Bn_FQZn0XW-hjRNO1naZkzS1X0Y39XMTnedioKU0PT2d05vDr1R9DSBswRnyZtLM9hetLOt6dUMIpqnCbsXHScMo5giiO8f7I-iR85dQkhwTunD6AhTRBKK4XH0s-i6oTeN6rXU_hqIvgJWCel_l0wNBPAbbStQGad2z_NPFwlFJQJXQkrdK1AbCxardfE2ThgQtVc2aLZWd8JeB79Gd6oH37XfgPm8mJ_HC2PXIGj-NHJA92AZZK_BubLD4-hBLVqnnoz3k-jr-3cXi4_xcvWhWJwtY0kZ8nFZoUwpREuoMkhzEeLBrK5CIhnNaYkRZQIxlOayVFBIlUOKEFIEUZKHAsIn0fO977Y1jo_JOo4yRAhLSJoGotgTlRGXfDwZN0Lzm4KxDRfWa9kqLhIsalGFxVhaqYpRFjoheVrBkmBCg9fp-LWh7FQlVe-taCem0ze93vDGXHFGMgrzLBi8GA2s-TYo5__R8kg1InSl-9oEM9lpJ_lZhlBOGbnxmv2FClelOi3Dv1XrUJ8IXk0EgfHqh2_E4Bwvvnz-f3a1nrIvD9iNEq3fONMOXpveTcF0D0prnLOqvksugXw3Grdp8N1o8HE0guzZYep3ottZwL8AZsQGqg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2725591544</pqid></control><display><type>article</type><title>Immunogenicity and reactogenicity of a third dose of BNT162b2 vaccine for COVID-19 after a primary regimen with BBIBP-CorV or BNT162b2 vaccines in Lima, Peru</title><source>Publicly Available Content (ProQuest)</source><source>PubMed Central</source><source>Coronavirus Research Database</source><creator>Vargas-Herrera, Natalia ; Fernández-Navarro, Manuel ; Cabezudo, Nestor E ; Soto-Becerra, Percy ; Solís-Sánchez, Gilmer ; Escobar-Agreda, Stefan ; Silva-Valencia, Javier ; Pampa-Espinoza, Luis ; Bado-Pérez, Ricardo ; Solari, Lely ; Araujo-Castillo, Roger V</creator><contributor>Hozbor, Daniela Flavia</contributor><creatorcontrib>Vargas-Herrera, Natalia ; Fernández-Navarro, Manuel ; Cabezudo, Nestor E ; Soto-Becerra, Percy ; Solís-Sánchez, Gilmer ; Escobar-Agreda, Stefan ; Silva-Valencia, Javier ; Pampa-Espinoza, Luis ; Bado-Pérez, Ricardo ; Solari, Lely ; Araujo-Castillo, Roger V ; Hozbor, Daniela Flavia</creatorcontrib><description>The administration of a third (booster) dose of COVID-19 vaccines in Peru initially employed the BNT162b2 (Pfizer) mRNA vaccine. The national vaccination program started with healthcare workers (HCW) who received BBIBP-CorV (Sinopharm) vaccine as primary regimen and elderly people previously immunized with BNT162b2. This study evaluated the reactogenicity and immunogenicity of the "booster" dose in these two groups in Lima, Peru. We conducted a prospective cohort study, recruiting participants from November to December of 2021 in Lima, Peru. We evaluated immunogenicity and reactogenicity in HCW and elderly patients previously vaccinated with either two doses of BBIBP-CorV (heterologous regimen) or BTN162b2 (homologous regimen). Immunogenicity was measured by anti-SARS-CoV-2 IgG antibody levels immediately before boosting dose and 14 days later. IgG geometric means (GM) and medians were obtained, and modeled using ANCOVA and quantile regressions. The GM of IgG levels increased significantly after boosting: from 28.5±5.0 AU/mL up to 486.6±1.2 AU/mL (p&lt;0.001) which corresponds to a 17-fold increase. The heterologous vaccine regimen produced higher GM of post-booster anti-SARS-CoV-2 IgG levels, eliciting a 13% increase in the geometric mean ratio (95%CI: 1.02-1.27) and a median difference of 92.3 AU/ml (95%CI: 24.9-159.7). Both vaccine regimens were safe and well tolerated. Previous COVID-19 infection was also associated with higher pre and post-booster IgG GM levels. Although both boosting regimens were highly immunogenic, two doses of BBIBP-CorV boosted with BTN162b2 produced a stronger IgG antibody response than the homologous BNT162b2 regimen in the Peruvian population. Additionally, both regimens were mildly reactogenic and well-tolerated.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0268419</identifier><identifier>PMID: 36251630</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Adverse and side effects ; Aged ; Aged patients ; Antibodies, Viral ; Antibody response ; Biology and Life Sciences ; BNT162 Vaccine ; Care and treatment ; Comorbidity ; Coronaviruses ; COVID-19 ; COVID-19 - prevention &amp; control ; COVID-19 vaccines ; COVID-19 Vaccines - adverse effects ; Drug dosages ; Drugs ; Evaluation ; Homology ; Humans ; IgG antibody ; Immunization ; Immunization, Secondary ; Immunoassay ; Immunogenicity ; Immunogenicity, Vaccine ; Immunoglobulin G ; Infections ; Medical personnel ; Medicine and Health Sciences ; mRNA ; mRNA Vaccines ; Older people ; Peru ; Population ; Prospective Studies ; Severe acute respiratory syndrome ; Severe acute respiratory syndrome coronavirus 2 ; Vaccines ; Vaccines, Synthetic ; Values</subject><ispartof>PloS one, 2022-10, Vol.17 (10), p.e0268419</ispartof><rights>COPYRIGHT 2022 Public Library of Science</rights><rights>2022 Vargas-Herrera et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 Vargas-Herrera et al 2022 Vargas-Herrera et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c692t-bd27ee26b0e7068a37139fd8417686b3269a29248cbe0ace806222e52658e0a23</citedby><cites>FETCH-LOGICAL-c692t-bd27ee26b0e7068a37139fd8417686b3269a29248cbe0ace806222e52658e0a23</cites><orcidid>0000-0002-3740-1962 ; 0000-0003-3637-2052 ; 0000-0001-7084-088X ; 0000-0002-0948-0114</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2725591544/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2725591544?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,38516,43895,44590,53791,53793,74412,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36251630$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Hozbor, Daniela Flavia</contributor><creatorcontrib>Vargas-Herrera, Natalia</creatorcontrib><creatorcontrib>Fernández-Navarro, Manuel</creatorcontrib><creatorcontrib>Cabezudo, Nestor E</creatorcontrib><creatorcontrib>Soto-Becerra, Percy</creatorcontrib><creatorcontrib>Solís-Sánchez, Gilmer</creatorcontrib><creatorcontrib>Escobar-Agreda, Stefan</creatorcontrib><creatorcontrib>Silva-Valencia, Javier</creatorcontrib><creatorcontrib>Pampa-Espinoza, Luis</creatorcontrib><creatorcontrib>Bado-Pérez, Ricardo</creatorcontrib><creatorcontrib>Solari, Lely</creatorcontrib><creatorcontrib>Araujo-Castillo, Roger V</creatorcontrib><title>Immunogenicity and reactogenicity of a third dose of BNT162b2 vaccine for COVID-19 after a primary regimen with BBIBP-CorV or BNT162b2 vaccines in Lima, Peru</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>The administration of a third (booster) dose of COVID-19 vaccines in Peru initially employed the BNT162b2 (Pfizer) mRNA vaccine. The national vaccination program started with healthcare workers (HCW) who received BBIBP-CorV (Sinopharm) vaccine as primary regimen and elderly people previously immunized with BNT162b2. This study evaluated the reactogenicity and immunogenicity of the "booster" dose in these two groups in Lima, Peru. We conducted a prospective cohort study, recruiting participants from November to December of 2021 in Lima, Peru. We evaluated immunogenicity and reactogenicity in HCW and elderly patients previously vaccinated with either two doses of BBIBP-CorV (heterologous regimen) or BTN162b2 (homologous regimen). Immunogenicity was measured by anti-SARS-CoV-2 IgG antibody levels immediately before boosting dose and 14 days later. IgG geometric means (GM) and medians were obtained, and modeled using ANCOVA and quantile regressions. The GM of IgG levels increased significantly after boosting: from 28.5±5.0 AU/mL up to 486.6±1.2 AU/mL (p&lt;0.001) which corresponds to a 17-fold increase. The heterologous vaccine regimen produced higher GM of post-booster anti-SARS-CoV-2 IgG levels, eliciting a 13% increase in the geometric mean ratio (95%CI: 1.02-1.27) and a median difference of 92.3 AU/ml (95%CI: 24.9-159.7). Both vaccine regimens were safe and well tolerated. Previous COVID-19 infection was also associated with higher pre and post-booster IgG GM levels. Although both boosting regimens were highly immunogenic, two doses of BBIBP-CorV boosted with BTN162b2 produced a stronger IgG antibody response than the homologous BNT162b2 regimen in the Peruvian population. Additionally, both regimens were mildly reactogenic and well-tolerated.</description><subject>Adverse and side effects</subject><subject>Aged</subject><subject>Aged patients</subject><subject>Antibodies, Viral</subject><subject>Antibody response</subject><subject>Biology and Life Sciences</subject><subject>BNT162 Vaccine</subject><subject>Care and treatment</subject><subject>Comorbidity</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 - prevention &amp; control</subject><subject>COVID-19 vaccines</subject><subject>COVID-19 Vaccines - adverse effects</subject><subject>Drug dosages</subject><subject>Drugs</subject><subject>Evaluation</subject><subject>Homology</subject><subject>Humans</subject><subject>IgG antibody</subject><subject>Immunization</subject><subject>Immunization, Secondary</subject><subject>Immunoassay</subject><subject>Immunogenicity</subject><subject>Immunogenicity, Vaccine</subject><subject>Immunoglobulin G</subject><subject>Infections</subject><subject>Medical personnel</subject><subject>Medicine and Health Sciences</subject><subject>mRNA</subject><subject>mRNA Vaccines</subject><subject>Older people</subject><subject>Peru</subject><subject>Population</subject><subject>Prospective Studies</subject><subject>Severe acute respiratory syndrome</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Vaccines</subject><subject>Vaccines, Synthetic</subject><subject>Values</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>COVID</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqNk--K1DAUxYso7rr6BqIBQRDsmCZN2nxZ2Bn_FQZn0XW-hjRNO1naZkzS1X0Y39XMTnedioKU0PT2d05vDr1R9DSBswRnyZtLM9hetLOt6dUMIpqnCbsXHScMo5giiO8f7I-iR85dQkhwTunD6AhTRBKK4XH0s-i6oTeN6rXU_hqIvgJWCel_l0wNBPAbbStQGad2z_NPFwlFJQJXQkrdK1AbCxardfE2ThgQtVc2aLZWd8JeB79Gd6oH37XfgPm8mJ_HC2PXIGj-NHJA92AZZK_BubLD4-hBLVqnnoz3k-jr-3cXi4_xcvWhWJwtY0kZ8nFZoUwpREuoMkhzEeLBrK5CIhnNaYkRZQIxlOayVFBIlUOKEFIEUZKHAsIn0fO977Y1jo_JOo4yRAhLSJoGotgTlRGXfDwZN0Lzm4KxDRfWa9kqLhIsalGFxVhaqYpRFjoheVrBkmBCg9fp-LWh7FQlVe-taCem0ze93vDGXHFGMgrzLBi8GA2s-TYo5__R8kg1InSl-9oEM9lpJ_lZhlBOGbnxmv2FClelOi3Dv1XrUJ8IXk0EgfHqh2_E4Bwvvnz-f3a1nrIvD9iNEq3fONMOXpveTcF0D0prnLOqvksugXw3Grdp8N1o8HE0guzZYep3ottZwL8AZsQGqg</recordid><startdate>20221017</startdate><enddate>20221017</enddate><creator>Vargas-Herrera, Natalia</creator><creator>Fernández-Navarro, Manuel</creator><creator>Cabezudo, Nestor E</creator><creator>Soto-Becerra, Percy</creator><creator>Solís-Sánchez, Gilmer</creator><creator>Escobar-Agreda, Stefan</creator><creator>Silva-Valencia, Javier</creator><creator>Pampa-Espinoza, Luis</creator><creator>Bado-Pérez, Ricardo</creator><creator>Solari, Lely</creator><creator>Araujo-Castillo, Roger V</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>COVID</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-3740-1962</orcidid><orcidid>https://orcid.org/0000-0003-3637-2052</orcidid><orcidid>https://orcid.org/0000-0001-7084-088X</orcidid><orcidid>https://orcid.org/0000-0002-0948-0114</orcidid></search><sort><creationdate>20221017</creationdate><title>Immunogenicity and reactogenicity of a third dose of BNT162b2 vaccine for COVID-19 after a primary regimen with BBIBP-CorV or BNT162b2 vaccines in Lima, Peru</title><author>Vargas-Herrera, Natalia ; Fernández-Navarro, Manuel ; Cabezudo, Nestor E ; Soto-Becerra, Percy ; Solís-Sánchez, Gilmer ; Escobar-Agreda, Stefan ; Silva-Valencia, Javier ; Pampa-Espinoza, Luis ; Bado-Pérez, Ricardo ; Solari, Lely ; Araujo-Castillo, Roger V</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c692t-bd27ee26b0e7068a37139fd8417686b3269a29248cbe0ace806222e52658e0a23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adverse and side effects</topic><topic>Aged</topic><topic>Aged patients</topic><topic>Antibodies, Viral</topic><topic>Antibody response</topic><topic>Biology and Life Sciences</topic><topic>BNT162 Vaccine</topic><topic>Care and treatment</topic><topic>Comorbidity</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 - prevention &amp; control</topic><topic>COVID-19 vaccines</topic><topic>COVID-19 Vaccines - adverse effects</topic><topic>Drug dosages</topic><topic>Drugs</topic><topic>Evaluation</topic><topic>Homology</topic><topic>Humans</topic><topic>IgG antibody</topic><topic>Immunization</topic><topic>Immunization, Secondary</topic><topic>Immunoassay</topic><topic>Immunogenicity</topic><topic>Immunogenicity, Vaccine</topic><topic>Immunoglobulin G</topic><topic>Infections</topic><topic>Medical personnel</topic><topic>Medicine and Health Sciences</topic><topic>mRNA</topic><topic>mRNA Vaccines</topic><topic>Older people</topic><topic>Peru</topic><topic>Population</topic><topic>Prospective Studies</topic><topic>Severe acute respiratory syndrome</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Vaccines</topic><topic>Vaccines, Synthetic</topic><topic>Values</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vargas-Herrera, Natalia</creatorcontrib><creatorcontrib>Fernández-Navarro, Manuel</creatorcontrib><creatorcontrib>Cabezudo, Nestor E</creatorcontrib><creatorcontrib>Soto-Becerra, Percy</creatorcontrib><creatorcontrib>Solís-Sánchez, Gilmer</creatorcontrib><creatorcontrib>Escobar-Agreda, Stefan</creatorcontrib><creatorcontrib>Silva-Valencia, Javier</creatorcontrib><creatorcontrib>Pampa-Espinoza, Luis</creatorcontrib><creatorcontrib>Bado-Pérez, Ricardo</creatorcontrib><creatorcontrib>Solari, Lely</creatorcontrib><creatorcontrib>Araujo-Castillo, Roger V</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological &amp; Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health &amp; Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science &amp; Engineering Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Advanced Technologies &amp; Aerospace Collection</collection><collection>Agricultural &amp; Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Meteorological &amp; Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agriculture Science Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest advanced technologies &amp; aerospace journals</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials science collection</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vargas-Herrera, Natalia</au><au>Fernández-Navarro, Manuel</au><au>Cabezudo, Nestor E</au><au>Soto-Becerra, Percy</au><au>Solís-Sánchez, Gilmer</au><au>Escobar-Agreda, Stefan</au><au>Silva-Valencia, Javier</au><au>Pampa-Espinoza, Luis</au><au>Bado-Pérez, Ricardo</au><au>Solari, Lely</au><au>Araujo-Castillo, Roger V</au><au>Hozbor, Daniela Flavia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunogenicity and reactogenicity of a third dose of BNT162b2 vaccine for COVID-19 after a primary regimen with BBIBP-CorV or BNT162b2 vaccines in Lima, Peru</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2022-10-17</date><risdate>2022</risdate><volume>17</volume><issue>10</issue><spage>e0268419</spage><pages>e0268419-</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>The administration of a third (booster) dose of COVID-19 vaccines in Peru initially employed the BNT162b2 (Pfizer) mRNA vaccine. The national vaccination program started with healthcare workers (HCW) who received BBIBP-CorV (Sinopharm) vaccine as primary regimen and elderly people previously immunized with BNT162b2. This study evaluated the reactogenicity and immunogenicity of the "booster" dose in these two groups in Lima, Peru. We conducted a prospective cohort study, recruiting participants from November to December of 2021 in Lima, Peru. We evaluated immunogenicity and reactogenicity in HCW and elderly patients previously vaccinated with either two doses of BBIBP-CorV (heterologous regimen) or BTN162b2 (homologous regimen). Immunogenicity was measured by anti-SARS-CoV-2 IgG antibody levels immediately before boosting dose and 14 days later. IgG geometric means (GM) and medians were obtained, and modeled using ANCOVA and quantile regressions. The GM of IgG levels increased significantly after boosting: from 28.5±5.0 AU/mL up to 486.6±1.2 AU/mL (p&lt;0.001) which corresponds to a 17-fold increase. The heterologous vaccine regimen produced higher GM of post-booster anti-SARS-CoV-2 IgG levels, eliciting a 13% increase in the geometric mean ratio (95%CI: 1.02-1.27) and a median difference of 92.3 AU/ml (95%CI: 24.9-159.7). Both vaccine regimens were safe and well tolerated. Previous COVID-19 infection was also associated with higher pre and post-booster IgG GM levels. Although both boosting regimens were highly immunogenic, two doses of BBIBP-CorV boosted with BTN162b2 produced a stronger IgG antibody response than the homologous BNT162b2 regimen in the Peruvian population. Additionally, both regimens were mildly reactogenic and well-tolerated.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>36251630</pmid><doi>10.1371/journal.pone.0268419</doi><tpages>e0268419</tpages><orcidid>https://orcid.org/0000-0002-3740-1962</orcidid><orcidid>https://orcid.org/0000-0003-3637-2052</orcidid><orcidid>https://orcid.org/0000-0001-7084-088X</orcidid><orcidid>https://orcid.org/0000-0002-0948-0114</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1932-6203
ispartof PloS one, 2022-10, Vol.17 (10), p.e0268419
issn 1932-6203
1932-6203
language eng
recordid cdi_plos_journals_2725591544
source Publicly Available Content (ProQuest); PubMed Central; Coronavirus Research Database
subjects Adverse and side effects
Aged
Aged patients
Antibodies, Viral
Antibody response
Biology and Life Sciences
BNT162 Vaccine
Care and treatment
Comorbidity
Coronaviruses
COVID-19
COVID-19 - prevention & control
COVID-19 vaccines
COVID-19 Vaccines - adverse effects
Drug dosages
Drugs
Evaluation
Homology
Humans
IgG antibody
Immunization
Immunization, Secondary
Immunoassay
Immunogenicity
Immunogenicity, Vaccine
Immunoglobulin G
Infections
Medical personnel
Medicine and Health Sciences
mRNA
mRNA Vaccines
Older people
Peru
Population
Prospective Studies
Severe acute respiratory syndrome
Severe acute respiratory syndrome coronavirus 2
Vaccines
Vaccines, Synthetic
Values
title Immunogenicity and reactogenicity of a third dose of BNT162b2 vaccine for COVID-19 after a primary regimen with BBIBP-CorV or BNT162b2 vaccines in Lima, Peru
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T00%3A01%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunogenicity%20and%20reactogenicity%20of%20a%20third%20dose%20of%20BNT162b2%20vaccine%20for%20COVID-19%20after%20a%20primary%20regimen%20with%20BBIBP-CorV%20or%20BNT162b2%20vaccines%20in%20Lima,%20Peru&rft.jtitle=PloS%20one&rft.au=Vargas-Herrera,%20Natalia&rft.date=2022-10-17&rft.volume=17&rft.issue=10&rft.spage=e0268419&rft.pages=e0268419-&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0268419&rft_dat=%3Cgale_plos_%3EA722869587%3C/gale_plos_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c692t-bd27ee26b0e7068a37139fd8417686b3269a29248cbe0ace806222e52658e0a23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2725591544&rft_id=info:pmid/36251630&rft_galeid=A722869587&rfr_iscdi=true